Anti-tumor necrosis factor-α therapy in undifferentiated spondyloarthritis (USpA)

Hsien Tzung Liao, Chun Hsiung Chen, Wei Sheng Chen, Hui Ting Lee, Chang Youh Tsai, Chung Tei Chou

Research output: Contribution to journalArticle

Abstract

Undifferentiated spondyloarthritis (USpA) include incomplete forms or early phases of definite seronegative spondyloarthritis (SpA) and cases of spondyloarthritis that remain undifferentiated. The treatment of SpA is more conditioned by the disease localization. Non-steroidal anti-inflammatory drugs and disease-modifying antirheumatic drugs are the main therapeutic agents for the treatment of peripheral arthritis in USpA. Tumor necrosis factor-α (TNF-α) has been detected in sacroiliac joints of patients with SpA. Anti-TNF-α therapy has been shown efficacious in patients with active ankylosing spondylitis (AS) and psoriatic arthritis. Similar to these SpA subtypes, therapeutic options in USpA are also limited. In those cases in which severe symptoms persist despite these treatments or when there is a severe axial involvement, biologic therapy (such as anti-TNF-α agents) represent an effective choice. In these patients, anti-TNF-α treatment raises the important possibility of blocking a shift from USpA to differentiated forms of spondyloarthritis.

Original languageEnglish
Pages (from-to)174-176
Number of pages3
JournalCurrent Rheumatology Reviews
Volume5
Issue number3
DOIs
Publication statusPublished - Aug 2009

Fingerprint

Tumor Necrosis Factor-alpha
Therapeutics
Sacroiliac Joint
Psoriatic Arthritis
Biological Therapy
Antirheumatic Agents
Ankylosing Spondylitis
Arthritis
Anti-Inflammatory Agents
Pharmaceutical Preparations

Keywords

  • Tumor necrosis factor-α (TNF-α)
  • Undifferentiated spondyloarthritis (USpA)

ASJC Scopus subject areas

  • Rheumatology

Cite this

Liao, H. T., Chen, C. H., Chen, W. S., Lee, H. T., Tsai, C. Y., & Chou, C. T. (2009). Anti-tumor necrosis factor-α therapy in undifferentiated spondyloarthritis (USpA). Current Rheumatology Reviews, 5(3), 174-176. https://doi.org/10.2174/157339709789208642

Anti-tumor necrosis factor-α therapy in undifferentiated spondyloarthritis (USpA). / Liao, Hsien Tzung; Chen, Chun Hsiung; Chen, Wei Sheng; Lee, Hui Ting; Tsai, Chang Youh; Chou, Chung Tei.

In: Current Rheumatology Reviews, Vol. 5, No. 3, 08.2009, p. 174-176.

Research output: Contribution to journalArticle

Liao, Hsien Tzung ; Chen, Chun Hsiung ; Chen, Wei Sheng ; Lee, Hui Ting ; Tsai, Chang Youh ; Chou, Chung Tei. / Anti-tumor necrosis factor-α therapy in undifferentiated spondyloarthritis (USpA). In: Current Rheumatology Reviews. 2009 ; Vol. 5, No. 3. pp. 174-176.
@article{50a777d427b54a2c902756f1e91f7283,
title = "Anti-tumor necrosis factor-α therapy in undifferentiated spondyloarthritis (USpA)",
abstract = "Undifferentiated spondyloarthritis (USpA) include incomplete forms or early phases of definite seronegative spondyloarthritis (SpA) and cases of spondyloarthritis that remain undifferentiated. The treatment of SpA is more conditioned by the disease localization. Non-steroidal anti-inflammatory drugs and disease-modifying antirheumatic drugs are the main therapeutic agents for the treatment of peripheral arthritis in USpA. Tumor necrosis factor-α (TNF-α) has been detected in sacroiliac joints of patients with SpA. Anti-TNF-α therapy has been shown efficacious in patients with active ankylosing spondylitis (AS) and psoriatic arthritis. Similar to these SpA subtypes, therapeutic options in USpA are also limited. In those cases in which severe symptoms persist despite these treatments or when there is a severe axial involvement, biologic therapy (such as anti-TNF-α agents) represent an effective choice. In these patients, anti-TNF-α treatment raises the important possibility of blocking a shift from USpA to differentiated forms of spondyloarthritis.",
keywords = "Tumor necrosis factor-α (TNF-α), Undifferentiated spondyloarthritis (USpA)",
author = "Liao, {Hsien Tzung} and Chen, {Chun Hsiung} and Chen, {Wei Sheng} and Lee, {Hui Ting} and Tsai, {Chang Youh} and Chou, {Chung Tei}",
year = "2009",
month = "8",
doi = "10.2174/157339709789208642",
language = "English",
volume = "5",
pages = "174--176",
journal = "Current Rheumatology Reviews",
issn = "1573-3971",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Anti-tumor necrosis factor-α therapy in undifferentiated spondyloarthritis (USpA)

AU - Liao, Hsien Tzung

AU - Chen, Chun Hsiung

AU - Chen, Wei Sheng

AU - Lee, Hui Ting

AU - Tsai, Chang Youh

AU - Chou, Chung Tei

PY - 2009/8

Y1 - 2009/8

N2 - Undifferentiated spondyloarthritis (USpA) include incomplete forms or early phases of definite seronegative spondyloarthritis (SpA) and cases of spondyloarthritis that remain undifferentiated. The treatment of SpA is more conditioned by the disease localization. Non-steroidal anti-inflammatory drugs and disease-modifying antirheumatic drugs are the main therapeutic agents for the treatment of peripheral arthritis in USpA. Tumor necrosis factor-α (TNF-α) has been detected in sacroiliac joints of patients with SpA. Anti-TNF-α therapy has been shown efficacious in patients with active ankylosing spondylitis (AS) and psoriatic arthritis. Similar to these SpA subtypes, therapeutic options in USpA are also limited. In those cases in which severe symptoms persist despite these treatments or when there is a severe axial involvement, biologic therapy (such as anti-TNF-α agents) represent an effective choice. In these patients, anti-TNF-α treatment raises the important possibility of blocking a shift from USpA to differentiated forms of spondyloarthritis.

AB - Undifferentiated spondyloarthritis (USpA) include incomplete forms or early phases of definite seronegative spondyloarthritis (SpA) and cases of spondyloarthritis that remain undifferentiated. The treatment of SpA is more conditioned by the disease localization. Non-steroidal anti-inflammatory drugs and disease-modifying antirheumatic drugs are the main therapeutic agents for the treatment of peripheral arthritis in USpA. Tumor necrosis factor-α (TNF-α) has been detected in sacroiliac joints of patients with SpA. Anti-TNF-α therapy has been shown efficacious in patients with active ankylosing spondylitis (AS) and psoriatic arthritis. Similar to these SpA subtypes, therapeutic options in USpA are also limited. In those cases in which severe symptoms persist despite these treatments or when there is a severe axial involvement, biologic therapy (such as anti-TNF-α agents) represent an effective choice. In these patients, anti-TNF-α treatment raises the important possibility of blocking a shift from USpA to differentiated forms of spondyloarthritis.

KW - Tumor necrosis factor-α (TNF-α)

KW - Undifferentiated spondyloarthritis (USpA)

UR - http://www.scopus.com/inward/record.url?scp=70449668995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449668995&partnerID=8YFLogxK

U2 - 10.2174/157339709789208642

DO - 10.2174/157339709789208642

M3 - Article

AN - SCOPUS:70449668995

VL - 5

SP - 174

EP - 176

JO - Current Rheumatology Reviews

JF - Current Rheumatology Reviews

SN - 1573-3971

IS - 3

ER -